Clinical and microbiological features of Clostridium difficile infections in France: The ICD-RAISIN 2009 national survey

Medecine et Maladies Infectieuses

Volumn 43, Issue 2, 2013, Pages 67-74

  Eckert, C ^a,b   Coignard, B ^c   Hebert, M ^c   Tarnaud, C ^c   Tessier, C ^a   Lemire, A ^a,b   Burghoffer, B ^a,b   Noel, D ^c   Barbut, F ^a,b  

^a Laboratoire associé au CNR des anaérobies et du botulisme   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSTITUT DE VEILLE SANITAIRE   (France)

Author keywords

Clostridium difficile; France; Incidence; PCR ribotypes

Indexed keywords

CLINDAMYCIN; ERYTHROMYCIN; GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; MOXIFLOXACIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL EVALUATION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EMERGENCY CARE; ENZYME ASSAY; FRANCE; GENE DELETION; HOSPITAL INFECTION; INCIDENCE; LONG TERM CARE; MICROBIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; REHABILITATION; STRAIN IDENTIFICATION; STRATEGIC PLANNING; TCDC GENE; TOXIN ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, MICROBIAL; FRANCE; HEALTH FACILITIES; HEALTH SURVEYS; HUMANS; INCIDENCE; LONG-TERM CARE; MICROBIAL SENSITIVITY TESTS; PATIENT ADMISSION; POPULATION SURVEILLANCE; RIBOTYPING;

EID: 84875813438     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.01.004     Document Type: Article

References (32)

1. O'Connor J.R., Johnson S., Gerding D.N. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 2009, 136(6):1913-1924.
2. Pepin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171(5):466-472.
3. McDonald L.C., Killgore G.E., Thompson A., Owens R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
4. Coignard B., Barbut F., Blanckaert K., Thiolet J.M., Poujol I., Carbonne A., et al. Emergence of Clostridium difficile toxinotype III, PCR-ribotype 027-associated disease, France, 2006. Euro Surveill 2006, 11(37). [PII: 3044]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=3044.
5. Birgand G., Blanckaert K., Carbonne A., Coignard B., Barbut F., Eckert C., et al. Investigation of a large outbreak of Clostridium difficile PCR-ribotype 027 infections in northern France, 2006-2007 and associated clusters in 2008-2009. Euro Surveill 2010, 15(25):8-13. [PII: 19597]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19597.
6. Thiolet J.M., Poujol I., Vaux S., Alleaume S., Coignard B. Le signalement des infections nosocomiales: un outil pour la détection et le suivi des infections émergentes en établissements de santé en France. Bull Epidemiol Hebd 2011, (15-17):193-197.
7. Barbut F., Gariazzo B., Bonne L., Lalande V., Burghoffer B., Luiuz R., et al. Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol 2007, 28(2):131-139.
8. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl. 6):2-18.
9. Kruskal W.H., Wallis W.A. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952, 47:583-621.
10. Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard-Seventh edition (M11A7) 2007, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. 2008.
12. Rupnik M., Avesani V., Janc M., von Eichel-Streiber C., Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998, 36(8):2240-2247.
13. Bidet P., Barbut F., Lalande V., Burghoffer B., Petit J.C. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999, 175(2):261-266.
14. Bauer M.P., Notermans D.W., van Benthem B.H., Brazier J.S., Wilcox M.H., Rupnik M., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
15. Daneman N., Stukel T.A., Ma X., Vermeulen M., Guttmann A. Reduction in Clostridium difficile infection rates after mandatory hospital public reporting: findings from a Longitudinal Cohort Study in Canada. PLoS Med 2012, 9(7):e1001268. [Internet]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398960/.
16. Miller B.A., Chen L.F., Sexton D.J., Anderson D.J. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011, 32(4):387-390.
17. Polgreen P.M., Yang M., Bohnett L.C., Cavanaugh J.E. A time-series analysis of Clostridium difficile and its seasonal association with influenza. Infect Control Hosp Epidemiol 2010, 31(4):382-387.
18. Jen M.H., Saxena S., Bottle A., Pollok R., Holmes A., Aylin P. Assessment of administrative data for evaluating the shifting acquisition of Clostridium difficile infection in England. J Hosp Infect 2012, 80(3):229-237. [Internet]. http://www.sciencedirect.com/science/article/pii/S0195670112000138.
19. Khanna S., Pardi D.S., Aronson S.L., Kammer P.P., Orenstein R., St. Sauver J.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107(1):89-95.
20. Hensgens M.P.M., Keessen E.C., Squire M.M., Riley T.V., Koene M.G.J., de Boer E., et al. Clostridium difficile infection in the community: a zoonotic disease?. Clin Microbiol Infect 2012, 18(7):635-645.
21. Wiegand P.N., Nathwani D., Wilcox M.H., Stephens J., Shelbaya A., Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012, 81(1):1-14.
22. Crobach M.J., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 2009, 15(12):1053-1066.
23. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
24. Barbut F., Mastrantonio P., Delmee M., Brazier J., Kuijper E., Poxton I. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 2007, 13(11):1048-1057.
25. Baines S.D., O'Connor R., Freeman J., Fawley W.N., Harmanus C., Mastrantonio P., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008, 62(5):1046-1052.
26. Poilane I., Cruaud P., Torlotin J.C., Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000, 6(3):155-156.
27. Brazier J.S., Raybould R., Patel B., Duckworth G., Pearson A., Charlett A., et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English hospitals, 2007-08. Euro Surveill 2008, 13(41):7-10. [PII: 19000]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19000.
28. Fenner L., Widmer A.F., Stranden A., Conzelmann M., Goorhuis A., Harmanus C., et al. First cluster of clindamycin-resistant Clostridium difficile PCR ribotype 027 in Switzerland. Clin Microbiol Infect 2008, 14(5):514-515.
29. Kuijper E.J., Barbut F., Brazier J.S., Kleinkauf N., Eckmanns T., Lambert M.L., et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008, 13(31). [PII: 18942]. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18942.
30. Bakker D., Corver J., Harmanus C., Goorhuis A., Keessen E.C., Fawley W.N., et al. Relatedness of human and animal Clostridium difficile PCR ribotype 078 isolates determined on the basis of multilocus variable-number tandem-repeat analysis and tetracycline resistance. J Clin Microbiol 2010, 48(10):3744-3749.
31. Noren T., Alriksson I., Akerlund T., Burman L.G., Unemo M. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010, 16(8):1104-1110.
32. Jones G., Taright N., Boelle P.Y., Marty J., Lalande V., Eckert C., et al. Accuracy of ICD-10 codes for surveillance of Clostridium difficile infections, France. Emerging Infect Dis 2012, 18(6):979-981.